Table 6 Number and percentages of monitoring and use of vasopressors or inotropes after propensity score matching
| Â | Â | Original data analysis | Sensitivity analysis | ||||
|---|---|---|---|---|---|---|---|
Low ASA-PS | High ASA-PS | ASD | Low ASA-PS | High ASA-PS | ASD | ||
ASA-PS 1 vs. 2 | IAM | 4885 (11.3) | 8391 (19.3) | 0.4 | 3148 (10.1) | 5226 (16.9) | 0.36 |
CVP | 600 (1.4) | 1456 (3.4) | 0.56 | 381 (1.2) | 876 (2.8) | 0.53 | |
IUC | 10,629 (24.5) | 14,668 (33.8) | 0.28 | 8506 (27.4) | 10,561 (34.0) | 0.20 | |
VI | 13,443 (31.0) | 16,388 (37.8) | 0.19 | 9679 (31.2) | 11,487 (36.9) | 0.16 | |
ASA-PS 1 vs. 3 | IAM | 2205 (17.0) | 8101 (61.0) | 1.25 | 1421 (16.2) | 5339 (60.9) | 1.28 |
CVP | 393 (3.0) | 1529 (11.5) | 0.88 | 250 (2.8) | 949 (10.8) | 0.87 | |
IUC | 9176 (33.0) | 12,689 (53.9) | 0.67 | 2183 (24.9) | 4256 (48.5) | 0.65 | |
VI | 4970 (37.4) | 9837 (59.0) | 0.55 | 3373 (38.4) | 5217 (59.5) | 0.53 | |
ASA-PS 2 vs. 3 | IAM | 8612 (36.6) | 16,497 (70.1) | 0.87 | 8627 (36.1) | 16,667 (69.7) | 0.87 |
CVP | 2324 (5.9) | 3854 (16.4) | 0.36 | 2301 (9.6) | 3895 (16.3) | 0.38 | |
IUC | 9176 (39.0) | 12,689 (53.9) | 0.38 | 9242 (38.7) | 12,872 (53.9) | 0.39 | |
VI | 12,951 (55.0) | 15,934 (67.7) | 0.34 | 12,937 (54.1) | 16,128 (67.5) | 0.35 | |